I am a board-certified hematologist specializing in the treatment of multiple myeloma and other plasma cell neoplasms. I have a particular research interest in early plasma cell disorders, including monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM), and understanding disease biology that may promote transition to frank symptomatic multiple myeloma in some individuals. My colleagues at Memorial Sloan Kettering and I offer a variety of treatment options (on and off clinical trial) for patients with multiple myeloma and high-risk SMM, including access to the latest novel drugs and immune-therapeutic approaches. Recent therapeutic advances have led to improved outcomes for people with multiple myeloma, and I am working on developing methods of monitoring minimal residual disease. By understanding mechanisms of tumor resistance with current available drugs and monitoring techniques, we aim to drive myeloma research forward and develop new strategies of tumor control or eradication.
- Clinical Expertise: Plasma Cell Disorders
- Languages Spoken: English
- Education: MD, University of Medicine and Dentistry of New Jersey; Robert Wood Johnson Medical School
- Residencies: Temple University Hospital and Fox Chase Center (Philadelphia)
- Fellowships: National Heart, Lung, and Blood Institute/National Cancer Institute
- Board Certifications: Internal Medicine; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Neha S. Korde
- A Phase I/II Study of VLX1570 and Dexamethasone in Patients with Recurrent or Persistent Multiple Myeloma
- A Phase Ib Study of Carfilzomib Give Once Weekly for Multiple Myeloma
- A Phase II Study of Daratumumab to Treat Smoldering Multiple Myeloma
- A Phase II Study of Lenalidomide as Maintenance Therapy for Plasma Cell Myeloma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more